Generation and transplantation of dopaminergic neurons derived from embryonic stem cells

Current Stem Cell Research and Therapy

Volumn 2, Issue 2, 2007, Pages 139-147

  Khanna, Aparna ^a   Swistowska, Anna Maria ^b   Rao, Mahendra S ^c,d   Zeng, Xianmin ^b  

^a RELIANCE LIFE SCIENCES PVT LTD   (India)

^b BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INVITROGEN CORPORATION   (United States)

Author keywords

Human embryonic stem cells; Neural Progenitors; Parkinson's disease; Transplantation; Ubiquitin

Indexed keywords

CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MONOAMINE OXIDASE INHIBITOR; NERVE CELL ADHESION MOLECULE;

BRAIN DEPTH STIMULATION; CELL DIFFERENTIATION; CELL SELECTION; CELL TYPE; COCULTURE; DOPAMINERGIC NERVE CELL; DRUG RESEARCH; DRUG SCREENING; EMBRYONIC STEM CELL; EXPERIMENTAL MODEL; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; MESENCEPHALON; MOTOR CONTROL; NERVE CELL DEGENERATION; NONHUMAN; PALLIDOTOMY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PURIFICATION; REVIEW; STEM CELL TRANSPLANTATION; STROMA CELL;

ANIMALS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; DOPAMINE; EMBRYONIC STEM CELLS; HUMANS; NEURONS; TISSUE THERAPY;

EID: 34249340851     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488807780599266     Document Type: Review

References (73)

1. Sethi KD. Clinical aspects of Parkinson disease. Curr Opin Neurol 2002; 15: 457-460.
2. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106-108.
3. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045-2047.
4. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605-608.
5. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-I gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256-259.
6. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304: 1158-1160.
7. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-980.
8. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Nature 2004; 44: 595-600.
9. Hirsch E, Graybiel AM, Agid YA. Melamized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988; 334: 345-348.
10. Purba JS, Hofman MA, Swaab DF. Decreased number of oxytocin-immunoreactive neurons in the paraventricular nucleus of the hypothalamus in Parkinson's disease. Neurology 1994; 44: 84-89.
11. Uhl GR, Hedreen JC, Price DL. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 1985; 35: 1215-1218.
12. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinsons disease. N Engl J Med 2004; 351: 2498-2508.
13. Kumar A, Huang Z, de la Fuente-Fernandez R. Mechanisms of motor complications in treatment of Parkinson's disease. Adv Neurol 2003; 91: 193-201.
14. Junghanns S, Glockler T, Reichmann H. Switching and combining of dopamine agonists. J Neurol 2004; 251 (Suppl 6): VI/19-23.
15. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev 2003; CD003735.
16. Kumar MJ, Andersen JK. Perspectives on MAO-B in aging and neurological disease: where do we go from here? Mol Neurobiol 2004; 30: 77-89.
17. Widnell KL, Comella C. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Mov Disord 2005; 20 (Suppl 11): S30-37.
18. Vitek JL, Bakay RA, Freeman A, et al. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann Neurol 2003; 53: 558-569.
19. Katayama Y, Kasai M, Oshima H, et al. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients. J Neurosurg 2001; 95: 213-221.
20. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-719.
21. Lindvall O, Hagell P. Cell therapy and transplantation in Parkinson's disease. Clin Chem Lab Med 2001; 39: 356-361.
22. Kordower JH, Freeman TB, Chen EY, et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord 1998; 13: 383-393.
23. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282: 1145-1147.
24. Perrier AL, Tabar V, Barberi T, et al. Derivation of midbrain dopamme neurons from human embryonic stem cells. Proc Natl Acad Sci USA 2004; 101: 12543-12548.
25. Buytaert-Hoefen KA, Alvarez E, Freed CR. Generation of tyrosine hydroxylase positive neurons from human embryonic stem cells after coculture with cellular substrates and exposure to GDNF. Stem Cells 2004; 22: 669-674.
26. Zeng X, Cai J, Chen J, et al. Dopaminergic differentiation of human embryonic stem cells. Stem Cells 2004; 22: 925-940.
27. Schulz TC, Noggle SA, Palmarini GM, et al. Differentiation of human embryonic stem cells to dopaminergic neurons in serumfree suspension culture. Stem Cells 2004; 22: 1218-1238.
28. Yan Y, Yang D, Zamowska ED, et al. Directed differentiation of dopaminergic neuronal subtypes from human embryonic stem cells. Stem Cells 2005; 23: 781-790.
29. Lee SH, Lumelsky N, Studer L, Auerbach JM, McKay RD. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol 2000; 18: 675-679.
30. Kim JH, Auerbach JM, Rodriguez-Gomez JA, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002; 418: 50-56.
31. Reubinoff BE, Itsykson P, Turetsky T, et al. Neural progenitors from human embryonic stem cells. Nat Biotechnol 2001; 19: 1134-1140.
32. Zhang SC, Wernig M, Duncan ID, Brustle O, Thomson JA. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol 2001; 19: 1129-1133.
33. Schulz TC, Palmarini GM, Noggle SA, Weiler DA, Mitalipova MM, Condie BG. Directed neuronal differentiation of human embryonic stem cells. BMC Neurosci 2003; 4: 27.
34. Kawasaki H, Mizuseki K, Nishikawa S, et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 2000; 28: 31-40.
35. Mayer-Proschel M, Kalyani AJ, Mujtaba T, Rao MS. Isolation of lineage-restricted neuronal precursors from multipotent neuroepithelial stem cells. Neuron 1997; 19: 773-785.
36. Pennartz S, Belvindrah R, Tomiuk S, et al. Purification of neuronal precursors from the adult mouse brain: comprehensive gene expression analysis provides new insights into the control of cell migration, differentiation, and homeostasis. Mol Cell Neurosci 2004; 25: 692-706.
37. Schwartz CM, Spivak CE, Baker SC, et al. NTera2: a model system to study dopaminergic differentiation of human embryonic stem cells. Stem Cells Dev 2005; 14: 517-534.
38. Barrett T, Xie T, Piao Y, et al. A murine dopamine neuronspecific cDNA library and microarray: increased COXI expression during methamphetamine neurotoxicity. Neurobiol Dis 2001; 8: 822-833.
39. Aubert J, Stavridis MP, Tweedie S, et al. Screening for mammalian neural genes via fluorescence-activated cell sorter purification of neural precursors from Sox1-gfp knock-in mice. Proc Natl Acad Sci USA 2003; 100 (Suppl 1): 11836-11841.
40. Fukuda H, Takahashi J, Watanabe K, et al. Fluorescence-activated cell sorting-based purification of embryonic stem cell-derived neural precursors averts tumor formation after transplantation. Stem Cells 2006; 24: 763-771.
41. Isacson O. The production and use of cells as therapeutic agents in neurodegenerative diseases. Lancet Neurol 2003; 2: 417-424.
42. Hagell P, Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. J Neuropathol Exp Neurol 2001; 60: 741-752.
43. Perlow MJ, Freed WJ, Hoffer BJ, Seiger A, Olson L, Wyatt RJ. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 1979; 204: 643-647.
44. Bjorklund A, Dunnett SB, Stenevi U, Lewis ME, Iversen SD. Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res 1980; 199: 307-333.
45. Freed WJ, Perlow MJ, Karoum F, et al. Restoration of dopaminergic function by grafting of fetal rat substantia nigra to the caudate nucleus: long-term behavioral, biochemical, and histochemical studies. Am Neurol 1980; 8: 510-519.
46. Cohen G. Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 1984; 5: 77-82.
47. Andrew R, Watson DG, Best SA, Midgley JM, Wenlong H, Petty RK. The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 1993; 18: 1175-1177.
48. Bjorklund LM, Sanchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 2002; 99: 2344-2349.
49. Ben-Hur T, Idelson M, Khaner H, et al. Transplantation of human embryonic stem cell-derived neural progenitors improves behavioral deficit in Parkinsonian rats. Stem Cells 2004; 22: 1246-1255.
50. Gage FH. Mammalian neural stem cells. Science 2000; 287: 1433-1438.
51. Han SS, Liu Y, Tyler-Polsz C, Rao MS, Fischer I. Transplantation of glial-restricted precursor cells into the adult spinal cord: survival, glial-specific differentiation, and preferential migration in white matter. Glia 2004; 45: 1-16.
52. Keirstead HS, Nistor G, Bernal G, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci 2005; 25: 4694-4705.
53. Liu S, Qu Y, Stewart TJ, et al. Embryonic stem cells differentiate into oligodendrocytes and myelinate in culture and after spinal cord transplantation. Proc Natl Acad Sci USA 2000; 97: 6126-6131.
54. Martin MJ, Muotri A, Gage F, Varki A. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med 2005; 11: 228-232.
55. Genbacev O, Krtolica A, Zdravkovic T, et al. Serum-free derivation of human embryonic stem cell lines on human placental fibroblast feeders. Fertil Steril 2005; 83: 1517-1529.
56. Ludwig TE, Levenstein ME, Jones JM, et al. Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 2006; 24: 185-187.
57. Ellerstrom C, Strehl R, Moya K, et al. Derivation of a xeno-free human embryonic stem cell line. Stem Cells 2006; 24: 2170-2176.
58. Valbuena D, Galan A, Sanchez E, et al. Derivation and characterization of three new Spanish human embryonic stem cell lines (VAL -3 -4 -5) on human feeder and in serum-free conditions. Reprod Biomed Online 2006; 13: 875-886.
59. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. Viable offspring derived from fetal and adult mammalian cells. Nature 1997; 385: 810-813.
60. Hochedlinger K, Jaenisch R. Monoclonal mice generated by nuclear transfer from mature B and T donor cells. Nature 2002; 415: 1035-1038.
61. Lee BC, Kim MK, Jang G, et al. Dogs cloned from adult somatic cells. Nature 2005; 436: 641.
62. Hwang WS, Roh SI, Lee BC, et al. Patient-specific embryonic stem cells derived from human SCNT blastocysts. Science 2005; 308: 1777-1783.
63. Civin CI, Rao MS. How many human embryonic stem cell lines are sufficient? A U.S. perspective. Stem Cells 2006; 24: 800-803.
64. Rao MS, Auerbach JM. Estimating human embryonic stem-cell numbers. Lancet 2006; 367: 650.
65. Taylor CJ, Bolton EM, Pocock S, Sharples ID, Pedersen RA, Bradley JA. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 2005; 366: 2019-2025.
66. Davila JC, Cezar GG, Thiede M, Strom S, Miki T, Trosko J. Use and application of stem cells in toxicology. Toxicol Sci 2004; 79: 214-223.
67. Klemm M, Schrattenholz A. Neurotoxicity of active compounds-establishment of hESC-lines and proteomics technologies for human embryo- and neurotoxicity screening and biomarker identification. Altex 2004; 21 (Suppl 3): 41-48.
68. Mee PJ, O'Brien CM, Thomson H, van der Sar S, Lakics V, Allsopp TE. Embryonic stem cells as a source of differentiated neural cells for pharmacological screens. Methods Mol Biol 2006; 329: 353-369.
69. Zeng X, Chen, J, Deng, X, et al. An in vitro model of human dopaminergic neurons derived from embryonic stem cells: MPP+ toxicity and GDNF neuroprotection. Neuropsychopharmacology 2006; 31(12): 2708-15.
70. Morizane A, Takahashi J, Takagi Y, Sasai Y, Hashimoto N. Optimal conditions for in vivo induction of dopaminergic neurons from embryonic stem cells through stromal cell-derived inducing activity. J Neurosci Res 2002; 69: 934-939.
71. Carpenter MK, Inokuma MS, Denham J, Mujtaba T, Chiu CP, Rao MS. Enrichment of neurons and neural precursors from human embryonic stem cells. Exp Neurol 2001; 172: 383-397.
72. Schuldiner M, Eiges R, Eden A, et al. Induced neuronal differentiation of human embryonic stem cells. Brain Res 2001; 913: 201-205.
73. Park CH, Minn YK, Lee JY, et al. In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. J Neurochem 2005; 92: 1265-1276.